Legal Representation
Attorney
Sarah Anne Keefe
USPTO Deadlines
Next Deadline
1028 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-05-24)
Due Date
May 24, 2028
Grace Period Ends
November 24, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
46 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 30, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Mar 30, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Mar 30, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 25, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 24, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 21, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Apr 20, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Apr 19, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Apr 8, 2022 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Apr 8, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 16, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 15, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Sep 15, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Sep 9, 2021 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Sep 9, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 13, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 9, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Apr 9, 2021 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Apr 9, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 9, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 7, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Oct 7, 2020 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Oct 7, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 1, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 30, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Mar 30, 2020 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Mar 30, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 11, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 9, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Oct 9, 2019 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 9, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 9, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 12, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 12, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 23, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 7, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Dec 12, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 12, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 12, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 12, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 19, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 19, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 19, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 11, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 26, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 22, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), hereditary ATTR amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1, Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), porphyria, hereditary ATTR amyloidosis, hepatic porphyrias, primary hyperoxaluria type 1
First Use Anywhere:
20180900
First Use in Commerce:
20180900
Classification
International Classes
005